Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023)

Kymera Therapeutics (KYMR) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $8000.0 as the latest value for Q3 2023.

  • For Q3 2023, Other Non-Current Liabilities fell 96.88% year-over-year to $8000.0; the TTM value through Sep 2023 reached $8000.0, down 96.88%, while the annual FY2022 figure was $248000.0, 275.76% up from the prior year.
  • Other Non-Current Liabilities hit $8000.0 in Q3 2023 for Kymera Therapeutics, down from $230000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $273000.0 in Q1 2022 and bottomed at $8000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 4 years is $161166.7, with a median of $165000.0 recorded in 2020.
  • Year-over-year, Other Non-Current Liabilities surged 275.76% in 2022 and then tumbled 96.88% in 2023.
  • Kymera Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2020, then plummeted by 34.0% to $66000.0 in 2021, then soared by 275.76% to $248000.0 in 2022, then tumbled by 96.77% to $8000.0 in 2023.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $8000.0, $230000.0, and $237000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.